
ABOUT CLINICAL INK
Clinical ink is the global life science company that brings data, technology, and patient science together.
Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials.
By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
For more information, visit www.clinicalink.com
FEATURED ARTICLES
-
Sticker prices often guide purchases, but there's a broader perspective that encompasses total cost. Use this calculator to compare prices of paper COAs or eCOAs, including ePROs, eDiaries, and eClinROs.
-
Remove the burdens and barriers inherent in clinical trial participation and deliver a more patient-centric experience with Clinical ink’s ePRO.
-
Explore the importance of involving caregivers in the care process and how ePRO technology can facilitate communication, tracking, and collaboration.
-
Discover effective strategies and solutions to overcome challenges in oncology studies and how to optimize trial design, patient recruitment, data management, and regulatory compliance in the ever-evolving field of oncology research.
-
Discover how this fit-for-purpose solution with direct data capture can improve any clinical trial execution, produce cleaner data, and ensure compliance and protocol adherence.
-
With the right eSource technology, discover how trial data can be aggregated, integrated, and classified to accelerate data analysis for insight-based decisions in real time.
-
eSource technologies allow Sponsors to center trials on patients and their needs as never before. This advancement of clinical trials can thus be based on comprehensive, actionable, patient-centered measures and assessments.
-
Given the decentralization of clinical trials and the many electronic sources of data now available, it is time for sponsors and contract research organizations to face the inevitable: EDCs need to be “sunsetted.”
-
CROs are able to expand their service offerings when using advanced data collection technologies. Explore how innovative tools like ePRO can help CROs.
-
At Clinical ink we bring data, technology, and patient science together to help our CRO partners advance clinical discovery.
-
Enable patient science via mobile assessments engineered by advanced clinical, software, data, and user experience experts. Power patient outcomes with Clinical ink.
-
Clinical ink’s eConsent technology optimizes your Informed Consent (ICF) process. By combining electronic form workflows and interactive question and answer sections, it offers a dynamic, easily understandable patient and user experience.
-
While paper diaries may appear cheaper, but there are hidden costs that make a digital eCOA solution much more affordable in your clinical trial.
-
Review the fundamental, crucial distinctions between Direct Data Capture and Electronic Data Capture that make a significant impact on clinical research workflows, data quality, and timelines.
-
The Clinical ink platform enables direct data capture (DDC), clinical outcome assessments (eCOA), patient reported outcomes (ePRO), and eConsent.
-
Improve trial efficiency, quality, and safety by accessing Clinical ink's large assortment of clinical outcomes assessments for a wide range of phases and therapeutic areas.
-
This ebook describes how electronic clinical outcomes assessments (eCOA), mobile digital assessments, and other innovative data capture technologies are able to “meet patients where they are” in Parkinson’s Disease trials – with increasingly objective, sensitive, and continuous measures.
-
eCOA translations don’t have to be overly complicated or time-consuming. When vendors work together, they create efficiencies that benefit both the sponsor and the patients. This article explains how translation specialist RWS and Clinical Ink collaborated to create a new tool that streamlines review and approval of translated eCOA screens.
-
Direct Data Capture (DDC) and Electronic Data Capture (EDC). They sound the same. But when you dig a little deeper, there are fundamental, crucial distinctions that make a significant difference in clinical research workflows, data quality, and timelines.
-
For infectious disease studies of any kind, the ability to accelerate trial timelines, while also providing high-quality data and reducing barriers to patient participation, is highly prized. And when the World Health Organization (WHO) declares a virus a pandemic, there’s no time to lose. Infectious disease drug developers must respond immediately to find treatment and prophylactic candidates and rapidly move them through the drug development process.
CONTACT INFORMATION
Clinical ink
632 W. 4th Street
Winston-Salem, NC 27101
UNITED STATES
Phone: 614-284-6804
Contact: Danielle Himelright
CASE STUDIES
-
Discover this breakthrough in providing evidence of disease status, progression, and treatment response for clinical development and medical practice.
-
Discover how transitioning multiple studies from on-site to at-home assessments improved patient retention and recruitment for a global neurology program.
-
Learn how a purpose-built solution designed to overcome the significant, but typical, challenges of a complex GI trial enables improved trial conduct and a better deployment experience.
-
A truly integrated eSource Solution, including DDC, eCOA, and eConsent, facilitates remote or decentralized clinical trials by ingesting data from multiple sources and consolidating it into a single data set.
-
A leading pharma company was planning a Phase III trial for a SARS-CoV-2 prophylactic therapy and needed to evaluate post-exposure prophylaxis and preemptive treatment in 1,000+ patients at 82 sites. Explore how eSource was rapidly deployed for clinical trial success.
-
Discover how multiple clinical outcomes assessments (COA) can be integrated into one automated tool for investigators to use during the patient visit.
-
Academic researchers and two biopharma leaders teamed up with Clinical ink in the WATCH-PD Study to test the power of at-home mobile devices to assess Parkinson’s Disease progression. The work, described here, is an important step in seeking regulators’ qualification of novel digital assessments in early Parkinson’s Disease.
-
Gain an in-depth understanding of how digital biomarkers are being developed for Parkinson's Disease, and an outlook on how advances in technology will drive a shift toward remote data collection in clinical trials.
-
Reach database lock in less than one month instead of a year. That’s what one large pharmaceutical company achieved by providing real-time remote access to validated clinical data.
-
In order to ensure a fluid experience for a patient, usability testing is a critical data point to consider. Addressing both a patient’s needs and access to a digital platform is key to data collection. TransPerfect, along with our partners from Parexel, Clinical Ink, and Health Psychology Research, recently published a poster at the Virtual ISPOR Europe 2020 conference that reviews the impact of moving from in-person to electronic data collection.
MEDIA
-
Watch as a panel of clinical experts specializing in diabetes care and clinical trial technology delve into the reasons why diabetes clinical trials have faced difficulties in keeping up with clinical care.
-
Understand the importance of platform-enabled real-time data capture and how to leverage AI and machine learning platforms to drive study insight into disease progression and treatment.
-
Clinical ink offers a best-in-class analytics platform to support the development and evaluation of digital biomarkers in clinical trials.
-
Deploy a smarter, faster, simpler eCOA with Clinical ink, powered by deep outcomes science expertise across many therapeutic areas.
-
Tune in to understand how to manage the complexity of assessments and data management in lupus investigations and how a centralized environment can make collaboration easier.
-
Beyond enabling data collection outside the clinic, new models are enhancing stakeholders' abilities to access more sensitive, frequent, and objective measures of Parkinson’s progression.
-
In this video, see firsthand fit-for-purpose mobile assessments and applications designed to measure endpoints in Parkinson’s Disease.